// App-Quantinova.ai

Su1176 : Added Value of Anti-Cbir-1 Antibodies to Differentiate IBD Unclassified From Ulcerative Colitis

Researchers

Presenter

  • Wei Xu

Principal Investigators

  • Joanne M. Stempak

  • Mark S. Silverberg

  • Gert A. Van Assche

Medical Centers

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON, Canada

  • Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

  • Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

  • Inflammatory bowel disease unclassified

Biomarkers

  • Cluster of differentiation 79A

  • Immunoglobulin G

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved